Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial

Nuccia Morici, GianMarco Podda, Simone Birocchi, Luca Bonacchini, Marco Merli, Michele Trezzi, Gianluca Massaini, Marco Agostinis, Giulia Carioti, Francesco Saverio Serino, Gianluca Gazzaniga, Daniela Barberis, Laura Antolini, Maria Grazia Valsecchi, View ORCID ProfileMarco Cattaneo
doi: https://doi.org/10.1101/2021.11.17.21266488
Nuccia Morici
1Intensive Coronary Care Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marco.cattaneo@unimi.it nuccia.morici@ospedaleniguarda.it
GianMarco Podda
2Unità di Medicina 2, ASST Santi Paolo e Carlo, Milan, Italy
3Dipartimento di Scienze della Salute, Università Degli Studi di Milano, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Birocchi
2Unità di Medicina 2, ASST Santi Paolo e Carlo, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Bonacchini
4Emergency Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Merli
5Divisione di Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Trezzi
6Struttura Operativa Complessa (SOC) Malattie Infettive II, AUSL Toscana Centro, Ospedale San Jacopo, Pistoia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianluca Massaini
7Struttura Operativa Semplice (SOS) Chirurgia vascolare, AUSL Toscana Centro, Ospedale San Jacopo, Pistoia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Agostinis
8Emergency Department, Ospedale San Carlo Borromeo, ASST Santi Paolo e Carlo, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giulia Carioti
8Emergency Department, Ospedale San Carlo Borromeo, ASST Santi Paolo e Carlo, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Saverio Serino
9ASL 4 Veneto, Covid Hospital, Jesolo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianluca Gazzaniga
10Postgraduate School of Clinical Pharmacology and Toxicology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Barberis
1Intensive Coronary Care Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Antolini
11Center of Bioinformatics, Biostatistics and Bioimaging, School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Grazia Valsecchi
11Center of Bioinformatics, Biostatistics and Bioimaging, School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Cattaneo
2Unità di Medicina 2, ASST Santi Paolo e Carlo, Milan, Italy
3Dipartimento di Scienze della Salute, Università Degli Studi di Milano, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marco Cattaneo
  • For correspondence: marco.cattaneo@unimi.it nuccia.morici@ospedaleniguarda.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. vs 40 mg o.d. enoxaparin in COVID-19 patients, between April 30, 2020 and April 25, 2021. Primary efficacy outcome was in-hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding. The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6·5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6·5, 95% CI, 1·5-11·6). Absence of concomitant DVT and imaging characteristics suggest that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically non-significant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm. In conclusion, no DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.

REGISTRATION ClinicalTrials.gov Identifier: NCT04366960

Ethics Commettee approvation number 75/2020

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ClinicalTrials.gov Identifier: NCT04366960

Funding Statement

Italfarmaco. The funding source had no roles in study design, data collection, data access, data analysis, data interpretation, decision to writing of the report and submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ASST Grande Ospedale Metropolitano Niguarda gave ethical approval for this work. Ethics Commettee approvation number: 75/2020

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 21, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
Nuccia Morici, GianMarco Podda, Simone Birocchi, Luca Bonacchini, Marco Merli, Michele Trezzi, Gianluca Massaini, Marco Agostinis, Giulia Carioti, Francesco Saverio Serino, Gianluca Gazzaniga, Daniela Barberis, Laura Antolini, Maria Grazia Valsecchi, Marco Cattaneo
medRxiv 2021.11.17.21266488; doi: https://doi.org/10.1101/2021.11.17.21266488
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
Nuccia Morici, GianMarco Podda, Simone Birocchi, Luca Bonacchini, Marco Merli, Michele Trezzi, Gianluca Massaini, Marco Agostinis, Giulia Carioti, Francesco Saverio Serino, Gianluca Gazzaniga, Daniela Barberis, Laura Antolini, Maria Grazia Valsecchi, Marco Cattaneo
medRxiv 2021.11.17.21266488; doi: https://doi.org/10.1101/2021.11.17.21266488

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (157)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (852)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8527)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1731)
  • Geriatric Medicine (166)
  • Health Economics (370)
  • Health Informatics (1232)
  • Health Policy (615)
  • Health Systems and Quality Improvement (465)
  • Hematology (196)
  • HIV/AIDS (367)
  • Infectious Diseases (except HIV/AIDS) (10258)
  • Intensive Care and Critical Care Medicine (550)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (209)
  • Neurology (1662)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (321)
  • Occupational and Environmental Health (450)
  • Oncology (918)
  • Ophthalmology (261)
  • Orthopedics (99)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (532)
  • Pharmacology and Therapeutics (245)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1751)
  • Public and Global Health (3814)
  • Radiology and Imaging (620)
  • Rehabilitation Medicine and Physical Therapy (316)
  • Respiratory Medicine (518)
  • Rheumatology (204)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (188)
  • Toxicology (36)
  • Transplantation (99)
  • Urology (74)